Kornimate/medical-research-clean huggingface dataset:
effects of teriparatide on distal radius fracture healing

Conditions: Colles' Fracture

Summary: effects of teriparatide on distal radius fracture healing


Eligibility criteria:
inclusion criteria: ambulatory, postmenopausal, women 45 to 85 years of age. postmenopausal is defined as at least 2 years without regular menses sustained a unilateral, dorsally angulated fracture of the distal radius within 10 days received conservative treatment of her distal radius fracture, including closed reduction and immobilization device (such as cast, splint, or brace) free of severe or chronically disabling conditions other than a distal radius fracture as determined by the investigator without language barrier, cooperative, expected to return for all follow-up procedures, and has given informed consent before entering the study and after being informed of the risks, medications and procedures to be used in the study. in the opinion of the investigator, the patient is willing to be trained and use the pen-injector daily, is able to satisfactorily use a pen-type injection delivery system, or is willing to receive daily subcutaneous injections from a care partner who has been trained to use the pen injector exclusion criteria: increased baseline risk of osteosarcoma history of a malignant neoplasm in the 5 years prior to visit 2, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitely treated have currently known, suspected, or history of other diseases that affect bone metabolism other than postmenopausal osteoporosis or cause secondary osteoporosis that has been clinically active in the 1 year prior to visit 2 have elevated serum calcium values active liver disease or clinical jaundice history of symptomatic nephro-or urolithiasis in the 2 years prior to visit 2 previous fractures or bone surgery in the currently fractured distal forearm joint disease such as rheumatoid arthritis or disabling osteoarthritis that clearly affect the function of the wrist and/or hand of the injured arm requirement for chronic treatment with nonsteroidal anti-inflammatory drugs defined as more than 3 consecutive months of any nsaid treatment treatment with: oral bisphosphonates for more than 18 months during the prior 3 years, or have received any oral or intravenous biphosphonate therapy within the last 2 months prior to screening. oral strontium ranelate for any duration systemic corticosteroids for more than 30 days (total) in the 6 months prior to visit 2, or any systemic corticosteroid dose in the 1 month prior to visit 2. ophthalmic, oric, topical, or nasally inhaled corticosteroid therapy may be used without these restrictions. fluoride at therapeutic doses (greater than or equal to 20mg/day) for more than 3 months during the last 2 years or for more than a total of 2 years, or any dosages within the 6 months prior to visit 2.
safety and antiviral study of ach126, 433 (b-l-fd4c) in adults with lamivudine-resistant chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: the purpose of this study was to determine the safety and antiviral hepatitis b virus (hbv) activity of ach126, 433 in the treatment of adults with lamivudine-resistant chronic hepatitis b.

evaluation of the safety and antiviral activity of 3 dose levels of ach126, 433 over a 12-week treatment in the population is described.

Eligibility criteria:
inclusion criteria * chronic hbv infection, known to be hepatitis b surface antigen (hbsag) positive ≥ 6 months * on lamivudine, either 100 or 150 milligrams daily for the treatment of chronic hepatitis b infection and exhibit a 2-3 log decrease in hbv deoxyribonucleic acid (dna) levels followed by a rebound of at least 1.5 log hbv dna or * achieved an hbv dna level of \ 100,000 copies/ml hbv dna, or * have a demonstrable lamivudine -resistant genotype regardless of treatment history. * hepatitis b e-antigen positive. * human immunodeficiency virus (hiv) negative. * serum alanine aminotransferase ≥ 1.5 and ≤ 10x times the upper limit of normal (uln). * hemoglobin ≥ 10 grams/deciliter or hematocrit ≥ 30% (in the absence of blood transfusions or erythropoietin treatment in the preceding 2 weeks). * platelet count \>75,000/cubic millimeters (in the absence of ongoing granulocyte colony-stimulating factor therapy). * serum creatinine \< 1.1x the uln. * negative radiologic screening test (ultrasound, computerized tomography scan, or magnetic resonance imaging) for hepatocellular carcinoma within 6 months prior to entry. * prothrombin time/international normalize ratio \< 2. * participants of reproductive capability must utilize an approved form of birth control. * all women of child-bearing capability must have a negative serum or urine pregnancy test (minimum sensitivity of 24 international units/liter of beta human chorionic gonadotropin) within 72 hours prior to the start of study medication. * participants must be able to provide written informed consent. * participant must be available for follow-up for a period of 20 weeks. exclusion criteria * hiv infection. * hepatitis c co-infection. * alcohol abuse. * pregnancy or breast-feeding. * inability to tolerate oral medication. * any clinical condition or prior therapy that, in the investigator's opinion, would make the participant unsuitable for the study or unable to comply with the dosing requirements. * use of any investigational drug. * participants with decompensated liver disease. * use of any concomitant herbal treatments.

Keywords: e-antigen positive lamivudine-resistant chronic hepatitis b achillion
immunogenicity and safety study of nbp606 in healthy toddlers

Conditions: Pneumococcal Infections

Summary: this study will assess the immunogenicity and safety of booster vaccination with nbp606 compared to the existing commercial vaccine, when given concomitantly with routine pediatric vaccinations.


Eligibility criteria:
inclusion criteria: * healthy infants who completed 3 doses of primary vaccination (nbp606_pcvi_iii_2013), available for follow-ups during the study period. * the lar (legally authorized representative) who understand the requirements of the study and voluntarily consent to participate in the study. exclusion criteria: * administration of other vaccines, except the ones provided in this study, within 1month prior to booster study * known hypersensitivity to any components of the pneumococcal vaccine * any confirmed or suspected immunosuppressive or immunodeficient conditions * coagulation disorder contraindicating im(intramuscular) vaccination * participation to another study
circulating biomarkers repository in adults diagnosed with primary and metastatic brain tumors

Conditions: Brain Tumor, Primary; Brain Metastases, Adult

Summary: the purpose of this protocol is to create a repository of blood samples from patients diagnosed with primary and metastatic brain tumors who are being seen in the department of radiation oncology at duke cancer center.

repository blood samples will be used to study the association of circulating biomarkers with radiation therapy outcomes.

Eligibility criteria:
inclusion criteria: * have a confirmed diagnosis of primary or metastatic brain tumor (histology or imaging as appropriate) exclusion criteria: * none
using human menstrual blood cells to treat acute lung injury caused by h7n9 bird flu virus infection

Conditions: Acute Lung Injury; Acute Respiratory Distress Syndrome (ARDS); Multiple Organ Failure

Summary: the purpose of this study is to determine whether human menstrual blood-derived stem cells are effective in the treatment of infection of h7n9 virus caused acute lung injury.

1. recruiting volunteers of h7n9 infection: age \> 18; patients signed with the informed consent; apache ii \> 20 score 2. patients infused with menstrual blood progenitor cells infusion dose: 1\~10×10\*7 cells/kg infusion frequency: 2 times a week, 2 weeks for infusion 3. test items and standard spirits lifted; pulmonary function improved; lung image injury improved

Eligibility criteria:
inclusion criteria: * clinical diagnosis of h7n9 infection * must be critical injured for lung tissues exclusion criteria: * cancer diseases * pregnancy * mental disorder * allergic constitution * severe inflammation
effectiveness of bupivacaine after laparoscopic cholecystectomy

Conditions: Postoperative Pain

Summary: evaluate the efficacy on postoperative pain of the positioning of a 0,5% bupivacaine soaked-tabotamp in gallbladder bed after videolaparoscopic cholecystectomy.


Eligibility criteria:
inclusion criteria: * age\>18 years old, asa 1 and 2 * gallbladder adenomatous polyposis and cholelithiasis with no byochemical, clinical and instrumental evidence of acute cholecystitis at the moment of surgery. exclusion criteria: * age\<18 years old * pregnancy * previous major surgery of the supramesocholic compartment * acute cholecystitis * choledocolitiasis * acute pancreatitis at the moment of surgery * laparotomic conversion during surgery

Keywords: cholecystectomy
a study for teriparatide in severe osteoporosis

Conditions: Osteoporosis, Postmenopausal; Osteoporosis

Summary: this observational study will evaluate the incidence of new vertebral and non vertebral fragility fractures in patients with severe osteoporosis treated with anabolic drugs. this study will also evaluate bmd, compliance to treatment, back pain and the health-related quality of life.

the participants should be treated with anabolic therapy for osteoporosis (teriparatide or pth 1-84) for 18 months and should be followed up for subsequent 6 months. the treatment is expected to improve bone mineral density, back pain and reduce the risk of new fractures due to osteoporosis. the outcomes will be evaluated by bone densitometry at the lumbar spine and femoral neck, by standard radiographs, by measurements of bone formation marker (p1np) and by questionnaires on back pain and quality of life. postmenopausal women and men over 21 years old may be included if they have: 1. at least 3 severe vertebral fractures 2. 2 severe vertebral fractures and 1 hip fracture 3. an incidental vertebral fracture or an hip fracture during treatment with antiresorptives prescribed for at least 12 months.

Eligibility criteria:
inclusion criteria: * postmenopausal women and men older than 21 years affected by severe osteoporosis with an incidental vertebral or hip fracture during treatment with an antiresorptive, or having 3 or more severe vertebral fractures or having 2 severe vertebral fractures and an historical hip fracture. exclusion criteria: * any contraindication for the use of antiosteoporotic drug * premenopausal women or men younger than 21 years
effects of aerobic exercise on lean non-alcoholic fatty liver disease (nafld)

Conditions: Non-alcoholic Fatty Liver Disease

Summary: nafld is increasingly being identified in lean individuals, especially in chinese population. among the nafld patients, the lean nafld accounts for 15.9%-23.0%. previous studies showed that the lean nafld individuals might have a higher risk of severe hepatic disease than those obese individuals. however, the effects of aerobic exercise on the reduction of liver fat content and metabolic risk factors in lean nafld individuals remain unknown. in this randomized controlled trial, we will examine the effect of a 3-month exercise training (aerobic exercise) on liver fat content and metabolic risk factors in lean nafld individuals.

the whole study is divided into four phases: recruitment phase, training phase (1 month, aim to gradually adapt patients to the target exercise intensity), implementation phase (3 months), and follow-up phase (9 months). and the subjects are randomly assigned to two groups: aerobic exercise intervention group and control group.

Eligibility criteria:
inclusion criteria: * 1. subjects with nafld determined by mri-pdff (liver fat\&gt;5%). 2. subjects with bmi\&lt;23 kg/m2. 3. subjects with inactive exercise before. 4. subjects with basic abilities of understanding, communication and writing. exclusion criteria: * 1. regular drinkers (consumed more than an average of 140 grams of ethanol per week in men and 70 grams in women during the past twelve months). 2. complicated with other liver diseases (i.e. acute or chronic viral hepatitis, liver cancer, liver cirrhosis, drug-induced liver diseases, and autoimmune hepatitis). 3. subjects with abnormal liver function (i.e. more than 3 times the upper limit of normal alanine aminotransferase and aspartate aminotransferase). 4. complicated with severe cardiovascular disease \[i.e. myocardial infarction, arrhythmia, heart failure (new york heart association iii or iv), uncontrolled hypertension (i.e. systolic blood pressure \&gt;180 mmhg, and/or diastolic blood pressure \&gt;100 mmhg)\]. 5. complicated with severe kidney disease or severe renal insufficiency or tumour. 6. currently pregnant or planning to be pregnant or breast feeding women. 7. participating in weight loss programs/exercise programs currently or during the past three months. 8. having any medical condition that would affect metabolism or limit exercise (i.e. diabetes, known hyperthyroidism or hypothyroidism). 9. having a medical condition that would limit exercise participation or alter heart rate during exercise or taking medication that would affect metabolism or weight loss (i.e. glucocorticoids, antithyroid drugs, hypoglycemic drugs, antihypertensive drugs). 10. having been doing regular physical exercise for the past three months (i.e. 3 times/week, \&gt;30 min/time). 11. subjects with poor adherence.

Keywords: lean nafld
culturally adapting cbt for east asian youth in ontario

Conditions: Anxiety; Depression

Summary: this mixed methods study proposes a culturally adapted cognitive behavioural therapy (ca-cbt) model for an east asian demographic in canada. the client population of east asian youth who have been diagnosed with anxiety and/or depression are the focus of the study. cbt has been proven as a very effective form of therapy, and when adapted can promote positive mental health outcomes for a growing and increasingly vulnerable population. developing a culturally adapted version of cbt (ca-cbt) for this population adds a practical treatment that improves access to culturally relevant care.

there is a major lack of culturally relevant mental health services for east asian youth in ontario and canada. beginning with a participatory/qualitative research approach, common themes amongst clients, caregivers, healthcare professionals, and community leaders, will divulge basic elements needed to develop a culturally adapted model of cognitive behavioural therapy. the information from the adapted model will be taught to participating psychologists who will deliver the therapy in a randomized control trial design, with feasibility testing of the intervention using a quantitative approach ensuing. immediate guidelines will then be developed for use by therapists working with east asian youth.

Eligibility criteria:
inclusion criteria: * self identification as east asian origin * between the ages of 12 to 21 * diagnosed as having depression and/or anxiety exclusion criteria: * have been affected by psychosis * have been affected by serious addiction * have been affected by cognitive impairment

Keywords: cognitive behavioral therapy cultural adaptation east asian youth
comutti - a research project dedicated to finding smart ways of using technology for a better tomorrow for everyone, everywhere.

Conditions: Autism Spectrum Disorder

Summary: according to world health organization, worldwide one in 160 children has an asd. about around 25% to 30% of children are unable to use verbal language to communicate (non-verbal asd) or are minimally verbal, i.e., use fewer than 10 words (mv-asd). the ability to communicate is a crucial life skill, and difficulties with communication can have a range of negative consequences such as poorer quality of life and behavioural difficulties. communication interventions generally aim to improve children's ability to communicate either through speech or by supplementing speech with other means (e.g., sign language, pictures, or aac - advanced augmented communication tools). individuals with non- verbal asd or mv-asd often communicate with people through vocalizations that in some cases have a self-consistent phonetic association to concepts (e.g., "ba" to mean "bathroom") or are onomatopoeic expressions (e.g., "woof" to refer to a dog). in most cases vocalizations sound arbitrary; even if they vary in tone, pitch, and duration depending it is extremely difficult to interpret the intended message or the individual's emotional or physical state they would convey, creating a barrier between the persons with asd and the rest of the world that originate stress and frustration. only caregivers who have long term acquaintance with the subjects are able to decode such wordless sounds and assign them to unique meanings. this project aims at defining algorithms, methods, and technologies to identify the communicative intent of vocal expressions generated by children with mv-asd, and to create tools that help people who are not familiar with the subjects to understand these individuals during spontaneous conversations.


Eligibility criteria:
inclusion criteria: * having a clinical diagnosis of autism spectrum disorder according to dsm-5 criteria * use fewer than 10 words exclusion criteria: * using any stimulant or non-stimulant medication affecting the central nervous system * having an identified genetic disorder * having vision or hearing problems * suffering from chronic or acute medical illness

Keywords: non-verbal autistic children minimally-verbal autistic children
interstitial cystitis: monitoring of the psychic state and counseling intervention in the covid-19 era

Conditions: Cystitis, Interstitial

Summary: the target population of this observational study is made up of all patients belonging to the interstitial cystitis pathway of the gemelli university hospital foundation - irccs, who have accepted to be subjected to remote monitoring and diagnostic investigation. the aim of the study is the evaluation of some outcome parameters at the time of enrollment (t0), and at the end (t1) of subjects affected by intersitial cystitis who have carried out a monitoring of the dimensions of the psychic sphere concerning: depression, trait anxiety, state anxiety , well-being, self-efficacy, resilience.the objective is also to evaluate the presence of evolutionary and maturational trends in the mental set-up of the people who participated in the individual counseling intervention.


Eligibility criteria:
inclusion criteria: * recruited subjects have a diagnosis of interstitial cystitis and are 18 years of age or older. exclusion criteria: * previous or current intellectual disability in accordance with the diagnostic and statistical manual of mental disorders, dsm-5. * patients who are unable to express consent and who do not have a caregiver who can give it for them.
effect of video-based exercise on premenstrual symptoms: a randomized controlled trial

Conditions: Premenstrual Syndrome; Stress

Summary: the aim of this study is to examine the effects of pilates based exercises on premenstrual symptom (pms) symptoms, perceived stress level and pain intensity.

the research is a quantitative study, and it is in the form of randomized controlled type research, one of the experimental research types. the sample of the study consisted of people who scored above the mild level according to the premenstrual syndrome scale (pmss) score and volunteered to participate in the study. participants will be divided into 2 groups as experimental group and control group by randomization method. sociodemographic information form, premenstrual syndrome scale (pmss), perceived stress scale (pss) and mcgill melzack pain scale (mpq) will be administered to the participants. pre- and post-intervention data were statistically analyzed and compared.

Eligibility criteria:
inclusion criteria: * being a woman between the ages of 18-35. * not having a condition that prevents exercise (not having orthopedic, cardiopulmonary, mental diseases, etc. that will prevent exercise). * not having given birth. * volunteer to participate in the study. * having a score above the mild level on the pmss score. * normal menstrual cycle. exclusion criteria: * having a condition that prevents you from exercising. * having a chronic disease. * being on any medication regularly. * being pregnant. * being in the menopausal period. * having a gynecological disease (endometriosis, ovarian cyst, pelvic infection, fibroid/uterine tumor etc.)

Keywords: stress pilates based exercises
comparison between gnrh agonist and gnrh antagonist protocols of ovarian stimulation in pcos patients

Conditions: Polycystic Ovary Syndrome; Ovarian Hyperstimulation Syndrome

Summary: the purpose of this study is to compare pregnancy rates and the occurrence of ohss in pcos patients who were treated with gnrh agonist and gnrh antagonist protocols ovarian stimulation during an ivf cycle. our hypothesis is that the gnrh antagonist protocol reduces the occurrence and severity of ohss compared to the gnrh agonist protocol.

women with polycystic ovarian syndrome (pcos) represent a group of patients at high risk of developing ovarian hyperstimulation syndrome (ohss), an iatrogenic complication of ovarian stimulation during ivf treatment. in contrast to mild ohss, severe ohss is a life-threatening complication, characterized by massive ovarian enlargement, ascites, pleural effusion, oliguria, haemoconcentration and thromboembolic phenomena. currently, no curative therapy for ohss is available and thus prevention is considered the most effective "treatment". several measures have been adopted to reduce the occurrence of the syndrome, the most effective being cycle cancellation and withholding of human chorionic gonadotropin (hcg), which seems to be the most critical factor for the development of ohss. comparison: this study aims to compare the development and severity of ohss, as well as ongoing pregnancy rates in pcos patients who received a flexible gnrh antagonist (ganirelix) protocol vs a long gnrh agonist (arvekap) protocol of ovarian stimulation.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of pcos (presence of oligo-ovulation/anovulation and polycystic ovaries) exclusion criteria: * normal responders * poor responders

Keywords: ohss pcos gnrh antagonist gnrh agonist